| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
5,366,000 |
| Market
Cap: |
7.51(M) |
| Last
Volume: |
140,704 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.506 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company focused on developing cancer immunotherapeutics for a range of cancer indications. Co.'s product candidates include galinpepimut-S (GPS) and nelipepimut-S (NPS). Co.'s primary product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets the Wilms tumor 1 protein, which is present in 20 or more cancer types. NPS is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 expressing cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
9,806 |
| Total Sell Value |
$0 |
$0 |
$0 |
$25,516 |
| Total People Sold |
0 |
0 |
0 |
3 |
| Total Sell Transactions |
0 |
0 |
0 |
3 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hillsberg Sanford |
Director |
– • – |
2011-04-13 |
4 |
A |
$0.00 |
$0 |
D/D |
135,159 |
141,159 |
|
- |
|
| Varanasi Ramani |
VP Business Development |
• – – |
2011-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
29,925 |
41,083 |
|
- |
|
| Tata Amy B |
Principlw Acctg Officer & Cont |
• – – |
2011-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
14,065 |
14,065 |
|
- |
|
| Pavco Pamela |
VP of Pharmaceutical Devlpmt |
• – – |
2011-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
33,563 |
44,940 |
|
- |
|
| Khvorova Anastasia |
Chief Science Officer |
• – – |
2011-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
43,053 |
60,559 |
|
- |
|
| Beerman Noah D |
CEO and President |
• • – |
2011-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
77,587 |
92,994 |
|
- |
|
| Cytrx Corp |
10% Owner |
– – • |
2010-12-29 |
4 |
AS |
$2.20 |
$5,706,538 |
D/D |
(2,593,881) |
0 |
|
- |
|
| Cytrx Corp |
10% Owner |
– – • |
2010-12-22 |
4 |
S |
$2.65 |
$1,325,000 |
D/D |
(500,000) |
2,593,881 |
|
- |
|
| Varanasi Ramani |
VP Business Development |
• – – |
2010-07-19 |
4 |
A |
$2.04 |
$11,424 |
D/D |
5,600 |
11,158 |
|
- |
|
| Varanasi Ramani |
VP Business Development |
• – – |
2010-07-19 |
4 |
S |
$2.05 |
$10,266 |
D/D |
(5,000) |
5,558 |
|
- |
|
| Pavco Pamela |
VP of Pharmaceutical Devlpmt. |
• – – |
2010-07-15 |
4 |
A |
$2.38 |
$11,921 |
D/D |
5,000 |
11,377 |
|
- |
|
| Khvorova Anastasia |
Chief Science Officer |
• – – |
2010-07-12 |
4 |
A |
$2.23 |
$22,300 |
D/D |
10,000 |
17,506 |
|
- |
|
| Beerman Noah D |
CEO and President |
• • – |
2010-07-09 |
4 |
B |
$2.23 |
$22,292 |
D/D |
10,000 |
15,407 |
2.81 |
- |
|
| Varanasi Ramani |
VP Business Development |
• – – |
2010-07-08 |
4 |
A |
$2.04 |
$10,200 |
D/D |
5,000 |
10,558 |
|
- |
|
| Cytrx Corp |
10% Owner |
– – • |
2010-06-30 |
4 |
S |
$2.55 |
$5,100,000 |
D/D |
(2,000,000) |
3,093,881 |
|
- |
|
| Samarsky Dmitry |
VP, Technology Development |
• – – |
2010-03-31 |
4 |
S |
$4.65 |
$18,977 |
D/D |
(4,081) |
0 |
|
- |
|
| Cytrx Corp |
10% Owner |
– – • |
2010-03-26 |
4 |
S |
$5.70 |
$3,847,500 |
D/D |
(675,000) |
5,093,881 |
|
- |
|
| Galliker Stephens S |
Director |
– • – |
2010-03-26 |
4 |
S |
$5.54 |
$83,100 |
D/D |
(15,000) |
10,000 |
|
- |
|
| Hillsberg Sanford |
Director |
– • – |
2010-03-26 |
4 |
S |
$5.66 |
$141,500 |
D/D |
(25,000) |
6,000 |
|
- |
|
| Varanasi Ramani |
VP Business Development |
• – – |
2010-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
5,558 |
5,558 |
|
- |
|
| Samarsky Dmitry |
VP, Technology Development |
• – – |
2010-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
4,081 |
4,081 |
|
- |
|
| Pavco Pamela |
VP of Pharmaceutical Devlpmt. |
• – – |
2010-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
6,377 |
6,377 |
|
- |
|
| Khvorova Anastasia |
Chief Science Officer |
• – – |
2010-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
7,506 |
7,506 |
|
- |
|
| Andrikopoulos Konstantinos |
VP, Legal |
• – – |
2010-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
5,750 |
5,750 |
|
- |
|
| Beerman Noah D |
CEO and President |
• • – |
2010-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
5,407 |
5,407 |
|
- |
|
269 Records found
|
|
Page 7 of 11 |
|
|
0.05 (3.7%) 
